BIO-RAD LABORATORIES INC
For the period ended Sep 30, 2024. Filed Oct 31, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 31, 2024
BIO-B$389.98+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share data)
| September 30, 2024 | December 31, 2023 | |
|---|---|---|
| ASSETS: · (Unaudited) | ||
| Cash and cash equivalents | $410,377 | $403,815 |
| Short-term investments | 1,212,081 | 1,203,327 |
| Restricted investments | 5,560 | 5,560 |
| Accounts receivable, less allowance for credit losses of $12,139 as of September 30, 2024 and $14,926 as of December 31, 2023 | 461,940 | 489,017 |
| Inventory | 804,276 | 780,517 |
| Prepaid expenses | 133,228 | 140,040 |
| Other current assets | 28,158 | 26,054 |
| Total current assets | 3,055,620 | 3,048,330 |
| Property, plant and equipment, net | 545,304 | 529,007 |
| Operating lease right-of-use assets | 173,866 | 194,730 |
| Goodwill, net | 415,100 | 413,569 |
| Purchased intangibles, net | 307,325 | 320,514 |
| Other investments | 6,002,635 | 7,698,070 |
| Other assets | 103,622 | 94,850 |
| Total assets | $10,603,472 | $12,299,070 |
Condensed Consolidated Balance Sheets
(continued)
(In thousands, except share data)
| September 30, 2024 | December 31, 2023 | |
|---|---|---|
| LIABILITIES AND STOCKHOLDERS’ EQUITY: · (Unaudited) | ||
| Accounts payable | $122,185 | $144,625 |
| Accrued payroll and employee benefits | 146,024 | 139,929 |
| Current maturities of long-term debt and notes payable | 1,262 | 486 |
| Income and other taxes payable | 43,625 | 35,759 |
| Current operating lease liabilities | 42,834 | 40,379 |
| Other current liabilities | 142,013 | 161,621 |
| Total current liabilities | 497,943 | 522,799 |
| Long-term debt, net of current maturities | 1,200,062 | 1,199,052 |
| Deferred income taxes | 1,076,058 | 1,475,495 |
| Operating lease liabilities | 143,919 | 165,478 |
| Other long-term liabilities | 197,631 | 195,113 |
| Total liabilities | 3,115,613 | 3,557,937 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value, 7,500,000 shares authorized; issued and outstanding - none | — | — |
| Class A common stock, shares issued 25,190,963 and 25,169,944 as of September 30, 2024 and December 31, 2023, respectively; shares outstanding 22,920,768 and 23,422,506 as of September 30, 2024 and December 31, 2023, respectively | 2 | 2 |
| Class B common stock, shares issued and outstanding, 5,074,909 as of September 30, 2024 and 5,095,930 as of December 31, 2023, respectively | 1 | 1 |
| Additional paid-in capital | 448,329 | 449,075 |
| Class A treasury stock at cost, 2,270,195 and 1,747,438 shares as of September 30, 2024 and December 31, 2023, respectively | (777,430) | (632,536) |
| Retained earnings | 8,132,231 | 9,260,629 |
| Accumulated other comprehensive loss | (315,274) | (336,038) |
| Total stockholders’ equity | 7,487,859 | 8,741,133 |
| Total liabilities and stockholders’ equity | $10,603,472 | $12,299,070 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.